Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab with Chemoradiation for Esophageal Cancer
NCT01307956Phase 2Terminated
- Sponsor
- University of Nebraska
- Start
- Feb 2011
- Primary completion
- Dec 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by University of Nebraska. Started Feb 2011; status: terminated.
02
Drugs
panitumumab
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01307956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01307956.